Cargando…
A surgical strategy for intrahepatic cholangiocarcinoma — the hilar first concept
PURPOSE: The present study assesses long-term overall survival (OS) and disease-free survival (DFS) after curative resection for intrahepatic cholangiocarcinoma (ICCA) depending on resection margin (RM) status and lymph node (LN) status. METHODS: Clinical data of all consecutively resected patients...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404569/ https://www.ncbi.nlm.nih.gov/pubmed/37544932 http://dx.doi.org/10.1007/s00423-023-03023-y |
_version_ | 1785085327750201344 |
---|---|
author | Nevermann, Nora Bode, Julia Vischer, Maxine Feldbrügge, Lina Knitter, Sebastian Krenzien, Felix Pelzer, Uwe Fehrenbach, Uli Auer, Timo Alexander Lurje, Georg Schmelzle, Moritz Pratschke, Johann Schöning, Wenzel |
author_facet | Nevermann, Nora Bode, Julia Vischer, Maxine Feldbrügge, Lina Knitter, Sebastian Krenzien, Felix Pelzer, Uwe Fehrenbach, Uli Auer, Timo Alexander Lurje, Georg Schmelzle, Moritz Pratschke, Johann Schöning, Wenzel |
author_sort | Nevermann, Nora |
collection | PubMed |
description | PURPOSE: The present study assesses long-term overall survival (OS) and disease-free survival (DFS) after curative resection for intrahepatic cholangiocarcinoma (ICCA) depending on resection margin (RM) status and lymph node (LN) status. METHODS: Clinical data of all consecutively resected patients with ICCA at a single high-volume center between 2005 and 2018 were collected. Minimum follow-up was 36 months. Perioperative and long-term oncological outcome was assessed. RESULTS: One hundred ninety-two cases were included in the analysis. Thirty- and 90-day-mortality was 5.2% (n = 10) and 10.9% (n = 21). OS was 26 months with 1-, 2-, and 5-year-OS rates of 72%, 53%, and 26%. One-, 2-, and 5-year-DFS rates were 54%, 42%, and 35% (N0 vs. N1: 29 vs. 9 months, p = 0.116). R1 was not found to be an independent risk factor for reduced survival in the overall cohort (p = 0.098). When differentiating according to the LN status, clear resection margins were significantly associated with increased DFS for N0 cases (50 months vs. 9 months, p = 0.004). For N1 cases, no significant difference in DFS was calculated for R0 compared to R1 cases (9 months vs. 9 months, p = 0.88). For N0 cases, clear resection margins > 10 mm were associated with prolonged OS (p = 0.048). CONCLUSION: For N1 cases, there was no significant survival benefit when comparing R0 versus R1, while the complication rate remained high for the extended resection types. In view of merging multimodal treatment, the hilar first concept assesses locoregional LN status for optimal surgical therapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00423-023-03023-y. |
format | Online Article Text |
id | pubmed-10404569 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-104045692023-08-08 A surgical strategy for intrahepatic cholangiocarcinoma — the hilar first concept Nevermann, Nora Bode, Julia Vischer, Maxine Feldbrügge, Lina Knitter, Sebastian Krenzien, Felix Pelzer, Uwe Fehrenbach, Uli Auer, Timo Alexander Lurje, Georg Schmelzle, Moritz Pratschke, Johann Schöning, Wenzel Langenbecks Arch Surg Research PURPOSE: The present study assesses long-term overall survival (OS) and disease-free survival (DFS) after curative resection for intrahepatic cholangiocarcinoma (ICCA) depending on resection margin (RM) status and lymph node (LN) status. METHODS: Clinical data of all consecutively resected patients with ICCA at a single high-volume center between 2005 and 2018 were collected. Minimum follow-up was 36 months. Perioperative and long-term oncological outcome was assessed. RESULTS: One hundred ninety-two cases were included in the analysis. Thirty- and 90-day-mortality was 5.2% (n = 10) and 10.9% (n = 21). OS was 26 months with 1-, 2-, and 5-year-OS rates of 72%, 53%, and 26%. One-, 2-, and 5-year-DFS rates were 54%, 42%, and 35% (N0 vs. N1: 29 vs. 9 months, p = 0.116). R1 was not found to be an independent risk factor for reduced survival in the overall cohort (p = 0.098). When differentiating according to the LN status, clear resection margins were significantly associated with increased DFS for N0 cases (50 months vs. 9 months, p = 0.004). For N1 cases, no significant difference in DFS was calculated for R0 compared to R1 cases (9 months vs. 9 months, p = 0.88). For N0 cases, clear resection margins > 10 mm were associated with prolonged OS (p = 0.048). CONCLUSION: For N1 cases, there was no significant survival benefit when comparing R0 versus R1, while the complication rate remained high for the extended resection types. In view of merging multimodal treatment, the hilar first concept assesses locoregional LN status for optimal surgical therapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00423-023-03023-y. Springer Berlin Heidelberg 2023-08-07 2023 /pmc/articles/PMC10404569/ /pubmed/37544932 http://dx.doi.org/10.1007/s00423-023-03023-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Nevermann, Nora Bode, Julia Vischer, Maxine Feldbrügge, Lina Knitter, Sebastian Krenzien, Felix Pelzer, Uwe Fehrenbach, Uli Auer, Timo Alexander Lurje, Georg Schmelzle, Moritz Pratschke, Johann Schöning, Wenzel A surgical strategy for intrahepatic cholangiocarcinoma — the hilar first concept |
title | A surgical strategy for intrahepatic cholangiocarcinoma — the hilar first concept |
title_full | A surgical strategy for intrahepatic cholangiocarcinoma — the hilar first concept |
title_fullStr | A surgical strategy for intrahepatic cholangiocarcinoma — the hilar first concept |
title_full_unstemmed | A surgical strategy for intrahepatic cholangiocarcinoma — the hilar first concept |
title_short | A surgical strategy for intrahepatic cholangiocarcinoma — the hilar first concept |
title_sort | surgical strategy for intrahepatic cholangiocarcinoma — the hilar first concept |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404569/ https://www.ncbi.nlm.nih.gov/pubmed/37544932 http://dx.doi.org/10.1007/s00423-023-03023-y |
work_keys_str_mv | AT nevermannnora asurgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept AT bodejulia asurgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept AT vischermaxine asurgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept AT feldbruggelina asurgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept AT knittersebastian asurgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept AT krenzienfelix asurgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept AT pelzeruwe asurgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept AT fehrenbachuli asurgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept AT auertimoalexander asurgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept AT lurjegeorg asurgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept AT schmelzlemoritz asurgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept AT pratschkejohann asurgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept AT schoningwenzel asurgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept AT nevermannnora surgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept AT bodejulia surgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept AT vischermaxine surgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept AT feldbruggelina surgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept AT knittersebastian surgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept AT krenzienfelix surgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept AT pelzeruwe surgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept AT fehrenbachuli surgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept AT auertimoalexander surgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept AT lurjegeorg surgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept AT schmelzlemoritz surgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept AT pratschkejohann surgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept AT schoningwenzel surgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept |